OR WAIT null SECS
September 10, 2020
The companies have signed an agreement for the production of two plasmids needed for the manufacture of CG01, a gene therapy for the treatment of drug-resistant focal epilepsy.
September 09, 2020
The company is investing $130 million to add Phase III through commercial-scale manufacturing suites to its gene therapy campus in Harmans, MD.
August 18, 2020
The cell banks were created using current good manufacturing practices and can be used each time CombiGene produces new plasmids for the production of its gene therapy, CG01.
August 06, 2020
The therapy, indicated for a rare form of B-cell non-Hodgkin’s lymphoma, was developed by Kite, a Gilead company, which will manufacture the therapy at its facility in El Segundo, CA.
August 02, 2020
The early success seen on the market for approved cell and gene therapies poses both technical and manufacturing challenges for pipeline candidates on the road to commercialization.
July 30, 2020
Sangamo will receive a $75 million upfront license fee payment and will be eligible to earn up to $720 million in other development and commercial milestone payments, including up to $420 million in development milestones and up to $300 million in commercial milestones.
July 13, 2020
This method is expected to help bring gene therapies to market faster, safer, and cheaper.
July 02, 2020
RNA is easier to manipulate than DNA but challenging to deliver to the right cells.
June 30, 2020
The site can now support customized product and bioprocess development and custom cell and gene therapy reagent manufacturing.
June 29, 2020
The companies are entering into a license agreement to provide CSL Behring with exclusive global rights to etranacogene dezaparvovec, uniQure’s investigational gene therapy for patients with hemophilia B.